Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Anniek Strijdhorst et al, adding:
“Immune checkpoint inhibitors and thrombosis: are antiphospholipid antibodies to blame?
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but they are associated with an increased risk of both venous and arterial thromboembolism. The mechanisms behind this remain poorly understood.
One hypothesis: ICI therapy might trigger the development of antiphospholipid antibodies, leading to hypercoagulability.
A new prospective study from the ITHACA cohort, published in RPTH Journal, puts this hypothesis to the test.
- Key findings from 40 patients assessed before and after 3 months of ICI therapy:
- No significant development of antiphospholipid antibody positivity after 3 months (8% at baseline vs 5% at 3 months)
- No patients developed a positive lupus anticoagulant
- Thrombin generation remained unchanged
- Only 1 patient developed VTE during follow-up
The short-term thrombotic risk associated with ICI therapy does not appear to be mediated by antiphospholipid antibodies, pointing researchers toward other mechanisms that still need to be uncovered.”
Title: Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study
Authors: Anniek Strijdhorst, Dorien M. Salet, Jente M. Schoenaker, Vossa van der Vegte, Tom T.P. Seijkens, Hanneke W.M. van Laarhoven, Rolf T. Urbanus, Nick van Es
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology